<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37668173</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2982</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurogastroenterology and motility</Title><ISOAbbreviation>Neurogastroenterol Motil</ISOAbbreviation></Journal><ArticleTitle>Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study.</ArticleTitle><Pagination><StartPage>e14658</StartPage><MedlinePgn>e14658</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/nmo.14658</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tenapanor, a first-in-class, minimally systemic inhibitor of intestinal sodium/hydrogen exchanger isoform 3 (NHE3), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults based on two randomized, placebo-controlled, phase III studies (T3MPO-1 [NCT02621892], T3MPO-2 [NCT02686138]). The open-label T3MPO-3 extension study (NCT02727751) enrolled patients who completed these studies to investigate long-term safety and tolerability of tenapanor.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients who completed T3MPO-1 (16&#x2009;weeks) or T3MPO-2 (26&#x2009;weeks) were eligible for enrollment in T3MPO-3. Patients in T3MPO-3 received open-label tenapanor 50&#x2009;mg twice a day for up to an additional 39 (T3MPO-1) or 26 (T3MPO-2) weeks. Treatment-emergent adverse events (TEAEs) were evaluated in the entire T3MPO-3 safety population and in patients who received a total of &#x2265;52&#x2009;weeks of tenapanor.</AbstractText><AbstractText Label="KEY RESULTS" NlmCategory="RESULTS">A total of 312 patients were enrolled in T3MPO-3; 90 received &#x2265;52&#x2009;weeks of tenapanor. TEAEs were reported in 117 (37.5%) patients in the safety population and in 52 (57.8%) patients who received &#x2265;52&#x2009;weeks of tenapanor. Diarrhea was the most common TEAE, occurring in 10.6% of the safety population and in 11.1% of patients who received &#x2265;52&#x2009;weeks of tenapanor. Most cases were mild or moderate in severity, with only two severe cases reported in the safety population. No deaths occurred during the T3MPO-3 study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tenapanor was tolerable over &#x2265;52&#x2009;weeks of treatment and showed similar safety to that seen in shorter studies. Combined results of the T3MPO studies indicate that tenapanor is a valuable new treatment option for patients with IBS-C.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Neurogastroenterology &amp; Motility published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lembo</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-4479-1188</Identifier><AffiliationInfo><Affiliation>Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedenberg</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Great Lakes Gastroenterology, Mentor, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogel</LastName><ForeName>Ronald P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Digestive Health Center of Michigan, Chesterfield, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edelstein</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ardelyx, Inc., Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Suling</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ardelyx, Inc., Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ardelyx, Inc., Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbaum</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Ardelyx, Inc., Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chey</LastName><ForeName>William D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Michigan Medicine, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Ardelyx, Inc.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurogastroenterol Motil</MedlineTA><NlmUniqueID>9432572</NlmUniqueID><ISSNLinking>1350-1925</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>WYD79216A6</RegistryNumber><NameOfSubstance UI="C000599417">tenapanor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074083">Sodium-Hydrogen Exchanger 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="N">Constipation</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074083" MajorTopicYN="N">Sodium-Hydrogen Exchanger 3</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">irritable bowel syndrome with constipation</Keyword><Keyword MajorTopicYN="N">long-term</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">tenapanor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37668173</ArticleId><ArticleId IdType="doi">10.1111/nmo.14658</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407. doi:10.1053/j.gastro.2016.02.031</Citation></Reference><Reference><Citation>Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018;113(Suppl 2):1-18. doi:10.1038/s41395-018-0084-x</Citation></Reference><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-917. doi:10.1016/S2468-1253(20)30217-X</Citation></Reference><Reference><Citation>Palsson OS, Whitehead W, T&#xf6;rnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262-1273.e3. doi:10.1053/j.gastro.2019.12.021</Citation></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99-114.e3. doi:10.1053/j.gastro.2020.04.014</Citation></Reference><Reference><Citation>Hungin APS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17(5):643-650. doi:10.1046/j.1365-2036.2003.01456.x</Citation></Reference><Reference><Citation>Quigley EMM, Horn J, Kissous-Hunt M, Crozier RA, Harris LA. Better understanding and recognition of the disconnects, experiences, and needs of patients with irritable bowel syndrome with constipation (BURDEN IBS-C) study: results of an online questionnaire. Adv Ther. 2018;35:967-980. doi:10.1007/s12325-018-0733-x</Citation></Reference><Reference><Citation>Ballou S, McMahon C, Lee HN, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019;17(12):2471-2478.e3. doi:10.1016/j.cgh.2019.08.016</Citation></Reference><Reference><Citation>DiBonaventura M, Sun SX, Bolge SC, Wagner JS, Mody R. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin. 2011;27(11):2213-2222. doi:10.1185/03007995.2011.623157</Citation></Reference><Reference><Citation>Stephenson JJ, Buono JL, Spalding WM, et al. Impact of irritable bowel syndrome with constipation on work productivity and daily activity among commercially insured patients in the United States. Value Health. 2014;17(7):A370. doi:10.1016/j.jval.2014.08.839</Citation></Reference><Reference><Citation>Taylor DCA, Abel JL, Martin C, et al. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the chronic constipation and IBS-C treatment and outcomes real-world research platform (CONTOR). J Med Econ. 2020;23(10):1072-1083. doi:10.1080/13696998.2020.1799816</Citation></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036</Citation></Reference><Reference><Citation>Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology. 2022;163(1):118-136. doi:10.1053/j.gastro.2022.04.016</Citation></Reference><Reference><Citation>Rangan V, Ballou S, Shin A, Camilleri M, Beth Israel Deaconess Medical Center GI Motility Working Group, Lembo A. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey. Gastroenterology. 2020;158(3):786-788.e1. doi:10.1053/j.gastro.2019.10.036</Citation></Reference><Reference><Citation>Mearin F, Caballero AM, Serra J, et al. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain. Gastroenterol Hepatol. 2019;42(3):141-149. doi:10.1016/j.gastrohep.2018.10.008</Citation></Reference><Reference><Citation>Spencer AG, Labonte ED, Rosenbaum DP, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):227ra36. doi:10.1126/scitranslmed.3007790</Citation></Reference><Reference><Citation>Markham A. Tenapanor: first approval. Drugs. 2019;79(17):1897-1903. doi:10.1007/s40265-019-01215-9</Citation></Reference><Reference><Citation>King AJ, Siegel M, He Y, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):eaam6474. doi:10.1126/scitranslmed.aam6474</Citation></Reference><Reference><Citation>Wang J, Larauche M, Siegel M, et al. Tenapanor attenuates increased macromolecule permeability in human colon monolayer cultures induced by inflammatory cytokines and human fecal supernatants. Gastroenterology. 2018;154(Suppl 1) S-326. doi:10.1016/S0016-5085(18)31424-0</Citation></Reference><Reference><Citation>Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020;115(2):281-293. doi:10.14309/ajg.0000000000000516</Citation></Reference><Reference><Citation>Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021;116(6):1294-1303. doi:10.14309/ajg.0000000000001056</Citation></Reference><Reference><Citation>U.S. Dept of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: irritable bowel syndrome - Clinical evaluation of drugs for treatment. 2012. U.S. Dept of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Accessed November 2, 2022. https://www.fda.gov/media/78622/download</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>